X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
PluriPain-PMS, an advanced, all natural anti-inflammatory and mood-enhancing Women’s Health formula to combat specific symptoms associated with the menstrual cycle.
Lead Product(s): Vitamin D,Calcium,Potassium
Therapeutic Area: Immunology Product Name: PluriPain-PMS
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2023
Details:
SFA-002 oral pill acts as down-regulating levels of pro-inflammatory cytokines involved in the pathogenesis of psoriasis including TNF-α, IL-23, IL-12, IL-17 and INF-γ, and down-regulating autoimmunity.
Lead Product(s): SFA-002,Vitamin D,Magnesium
Therapeutic Area: Dermatology Product Name: SFA-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
SFA002 is a new oral therapeutic agent for the treatment of mild-moderate psoriasis. SFA-002 is a potential multi-target and disease-modifying therapeutic that has demonstrated efficacy, safety and durability in Phase 1a studies.
Lead Product(s): SFA-002,Vitamin D,Magnesium
Therapeutic Area: Dermatology Product Name: SFA-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have previously been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in Company's European Phase IIb trial.
Lead Product(s): GAD65-Alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2022
Details:
The diabetes vaccine Diamyd® (GAD-alum) is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA.
Lead Product(s): GAD65-Alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
Primary endpoints of safety and tolerability were met in Phase II clinical trial GADinLADA, in which diabetes vaccine Diamyd (GAD-alum) was administered directly into lymph node of 14 patients aged 30 to 70 years with autoimmune form of diabetes called LADA.
Lead Product(s): GAD-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. The Phase III trial DIAGNODE-3, with a planned start date later during 2021 and primary completion end of 2025.
Lead Product(s): rhGAD65,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
The results support a precision medicine approach with Diamyd® where significant effect on the preservation of endogenous insulin producing capacity and improved blood glucose control was seen in individuals that carry a specific genotyp, HLA DR3-DQ2.
Lead Product(s): GAD-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The patients, diagnosed with type 1 diabetes, have been given the diabetes vaccine Diamyd® directly into the lymph node on three occasions, one month apart, in combination with oral vitamin D (or its placebo) during four months, starting 30 days prior to the first injection.
Lead Product(s): GAD65-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
All 50 patients who participated in the extension of Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd® have now made their 24-month visit, and data will be presented in early July.
Lead Product(s): Recombinant human glutamic acid decarboxylase,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Icon Plc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
The clinical Phase II trial GADinLADA, where the diabetes vaccine Diamyd® is administered directly into the lymph node in patients with the autoimmune form of diabetes LADA, is fully recruited, and the first results from the trial are planned to be announced in 2022.
Lead Product(s): GAD-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2021
Details:
Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2.
Lead Product(s): GAD-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Details:
The trial is designed to confirm the effect and safety of Diamyd® in individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype.
Lead Product(s): GAD-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
Results from the phase IIb trial DIAGNODE-2 with intralymphatic administration of Diamyd® and meta-analysis comprising data from more than 600 patients treated with Diamyd® showing treatment effect in individuals carrying the HLA DR3-DQ2 haplotype, will be presented.
Lead Product(s): GAD-alum,Vitamin D
Therapeutic Area: Endocrinology Product Name: Diamyd
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
